- Home
- HIVE vs ARCT Comparison
HIVE vs ARCT Comparison
Compare HIVE & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- ARCT
- Stock Information
- Founded
- HIVE 1987
- ARCT 2013
- Country
- HIVE Canada
- ARCT United States
- Employees
- HIVE N/A
- ARCT N/A
- Industry
- HIVE
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- HIVE
- ARCT Health Care
- Exchange
- HIVE Nasdaq
- ARCT Nasdaq
- Market Cap
- HIVE 527.8M
- ARCT 602.7M
- IPO Year
- HIVE N/A
- ARCT N/A
- Fundamental
- Price
- HIVE $3.35
- ARCT $19.07
- Analyst Decision
- HIVE Strong Buy
- ARCT Strong Buy
- Analyst Count
- HIVE 6
- ARCT 7
- Target Price
- HIVE $7.42
- ARCT $65.00
- AVG Volume (30 Days)
- HIVE 9.6M
- ARCT 380.9K
- Earning Date
- HIVE 02-11-2025
- ARCT 11-07-2024
- Dividend Yield
- HIVE N/A
- ARCT N/A
- EPS Growth
- HIVE N/A
- ARCT N/A
- EPS
- HIVE N/A
- ARCT N/A
- Revenue
- HIVE $123,022,000.00
- ARCT $160,399,000.00
- Revenue This Year
- HIVE N/A
- ARCT $7.33
- Revenue Next Year
- HIVE N/A
- ARCT $4.71
- P/E Ratio
- HIVE N/A
- ARCT N/A
- Revenue Growth
- HIVE 55.97
- ARCT N/A
- 52 Week Low
- HIVE $2.18
- ARCT $14.30
- 52 Week High
- HIVE $5.54
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- HIVE 46.58
- ARCT 61.79
- Support Level
- HIVE $2.76
- ARCT $16.01
- Resistance Level
- HIVE $3.14
- ARCT $17.25
- Average True Range (ATR)
- HIVE 0.25
- ARCT 1.24
- MACD
- HIVE 0.01
- ARCT 0.32
- Stochastic Oscillator
- HIVE 42.45
- ARCT 98.15
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.